A Study to Evaluate ALN-AGT01 RVR in Adult Patients With Mild to Moderate Hypertension Pretreated With Zilebesiran

A Phase 2, Randomized, Double-blind, Placebo-controlled, Single Dose Study of the Efficacy, Pharmacodynamics, and Safety of ALN-AGT01 RVR in Adult Patients With Mild to Moderate Hypertension Pretreated With Zilebesiran

The purpose of this study is to evaluate the efficacy, pharmacodynamics (PD), and safety of ALN-AGT01 RVR in participants with mild to moderate hypertension pretreated with zilebesiran.

This study will be conducted in 2 parts:

• Part A: Single dose (SD), dose-ranging part in adults with mild to moderate hypertension.
• Part B: SD in adults with mild to moderate hypertension.

Part A: Inclusion Criteria

• Is an adult participant with a mean seated office systolic blood pressure (SBP) of at least 130 mmHg and no more than than 170 mmHg
• Either not taking antihypertensive medication or on stable therapy with up to 2 antihypertensive medications

Part B: Inclusion Criteria

• Is an adult participant with a mean seated office SBP of at least 140 mmHg and no more than 170 mmHg
• Has discontinued all prior antihypertensive medication other than a calcium channel blocker (CCB) and/or thiazide/thiazide-like diuretic (if taking) for at least 3 weeks

Both Parts: Exclusion Criteria

• Has known secondary hypertension or serum potassium more than 5 mmol/L
• Has an estimated glomerular filtration rate (eGFR) less than 30 mL/min/1.73m^2

Note: other protocol defined inclusion / exclusion criteria apply